Non-invasive tests are becoming central to how doctors manage metabolic dysfunction-associated steatotic liver disease. They guide risk assessment, help determine which patients should be treated, shape referral pathways and decide who is recruited into clinical trials. As drug treatments for metabolic dysfunction-associated steatohepatitis, or MASH, become more widely available, accurately identifying the stage of liver fibrosis has grown considerably in importance.
In clinical trials of MASH medications, the central objective is usually to identify patients with substantial fibrosis, defined as stage F2 or higher, or advanced fibrosis, defined as stage F3 or higher. These are the patients most likely to benefit from pharmacological therapy. Because liver biopsy is invasive, clinicians and researchers rely on blood-based and imaging-based tools to estimate fibrosis stage without it, and those estimates now carry real consequences for who receives treatment.
The commentary, published in The Lancet, argues that the performance of these tests in everyday clinical practice may not match the results reported in trial settings. Patients enrolled in studies are typically selected and followed under controlled conditions. Patients seen in routine care tend to be more varied in their characteristics, their other medical conditions and the follow-up they receive. That difference matters because decisions about treatment eligibility and specialist referral depend on how reliably these tools classify individual patients.
The authors stress that clinicians need to understand the limits of non-invasive tests when they interpret results for a given patient. A test that classifies patients accurately in a trial population may misclassify some of the people a general practice or hospital clinic sees, and a misclassified patient may be denied treatment or referral that would have helped. The commentary frames the question as one of matching the tools used to find eligible patients in trials with the realities of routine medicine before those tools are relied on in everyday care.
As treatment options expand, the accuracy of fibrosis staging will shape which patients receive therapy and which are sent for specialist assessment. The commentary positions careful evaluation of these tests as a necessary step in translating trial findings into everyday practice, so that the benefits seen in research reach the patients who need them.
13
